ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference

  ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference

Leerink Swann Global Healthcare Conference 2013

Business Wire

WOBURN, Mass. -- February 7, 2013

ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at
the Leerink Swann Global Healthcare Conference on Thursday, February 14, 2013
at 1:30 p.m. The presentation will be web cast and may be accessed through the
investor relations section of the Company’s website,

About ArQule

ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes ARQ 087, designed to inhibit fibroblast growth factor receptor, ARQ
621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736, designed
to inhibit the RAF kinases. ArQule’s current discovery efforts, which are
based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the
identification of novel kinase inhibitors that are potent, selective and do
not compete with ATP (adenosine triphosphate) for binding to the kinase.


ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
Press spacebar to pause and continue. Press esc to stop.